On June 5, BrainNow Medical-B rose 8.33% in regular trading, trading at HKD 2.64 per share, with trading volume of approximately HKD 94.47 million.

On the news front, the brain-computer interface (BCI) industry has seen a series of positive developments recently. China's first invasive BCI medical device registration certificate has been approved for market launch, accelerating the industry's commercialization pathway, with capital intensively investing in leading projects. BrainNow Medical, as a cognitive disorder digital therapeutics company combining brain science with AI technology, is viewed by the market as a BCI concept-linked stock.

Notably, the stock had previously declined sharply to historic lows following shareholder disposals and discounted block trades. On May 15, a shareholder sold 36 million shares at HKD 3.22, followed by pre-market block transactions at significant discounts to closing prices on May 20 and subsequent sessions. The current rebound may therefore also carry characteristics of an oversold recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)